Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Neoantigen-specific CD4 tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake CeccarelliSee the full list of authors
6 October 2023
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survivalVedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, Manar S Shafat, Amaia Cadinanos Garai, Louisa Green, Alastair Hotblack, Fred Arce Vargas, Karl S Peggs, Anniek B van der Waart, Harry Dolstra, Martin A Pule, Claire Roddie
13 September 2023
Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cellsKaren Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
7 September 2023
Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune responseYi-Na Wang, Yuan-Yuan Wang, Jin Wang, Wen-Juan Bai, Nai-Jun Miao, Jing Wang
31 August 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kristen M O'Dwyer, Martha L Arellano, Yi Lin, Maria R BaerSee the full list of authors
30 August 2023
Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumorGe Gao, Weiting Liao, Pei Shu, Qizhi Ma, Xia He, Benxia Zhang, Diyuan Qin, Yongsheng Wang
17 August 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, Ulla Kring Hansen, Maria Ormhøj, Alexander Tyron, Agnete W P Jensen, Mohammad Kadivar, Amalie Kai Bentzen, Kamilla K Munk, Gitte N Aasbjerg, Jeppe S H Ternander, Christina Heeke, Tripti Tamhane, Christian SchmessSee the full list of authors
16 August 2023
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectinZhijie Zhang, Chang Liu, Muhan Wang, Rongcheng Sun, Zhe Yang, Zhen Hua, Yushuang Wu, Mengting Wu, Hang Wang, Wen Qiu, Hongping Yin, Meijia Yang
16 August 2023
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomasNicholas P Tschernia, Hillary Heiling, Allison M Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne W Beaven, Jonathan S Serody, William A Wood, Barbara Savoldo, Natalie S Grover
1 August 2023
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemiaJingjing Wen, Yanxin Chen, Jiajie Yang, Chunye Dai, Shenjie Yu, Wenting Zhong, Lilin Liu, Chengguanng He, Wenmin Zhang, Ting Yang, Lingfeng Liu, Jianda Hu
31 July 2023